Datar Cancer Genetics



Most frequent questions and answers
During Exacta™ analysis, the samples submitted by the patient (e.g., fresh tissue, FFPE blocks, blood) are analysed to identify vulnerabilities of cancer, for which various drugs may exist. Based on the established efficacy and safety profile, a preference list of these drugs (single drugs or combinations) is assigned for each patient. This is therapy recommendation and is included as an integral part of every Exacta™ report.

Therapy recommendation is not a prescription. It is a patient-specific recommendation of drugs and drug combinations with a higher potential for success. Based on the therapy recommendation, as well as information from the complete Exactaâ„¢ report, the treating oncologist must evaluate the suitability of the therapy choice(s) as well as the health and fitness of the patient and make a final treatment decision. The selected treatment must be administered only under the supervision of the treating oncologist.

The therapy recommendation will include only those drugs which have been approved by the FDA for use in a patient’s or another cancer type, as well as those drugs that are used to treat non-cancerous conditions. Investigational anti-cancer drugs will never be recommended.

While it is not possible to predict the response of an individual patient, our clinical studies have shown that about 114 out of 126 patients who received Exacta™ based treatments obtained clinical benefit (CBR = 90.5%).

Exacta™ is a very recent technological breakthrough and we will be happy to appraise your doctor / oncologist about its utility. Please contact us for additional details.